A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma

European Urology

Volumn 66, Issue 3, 2014, Pages 529-541

  Leow, Jeffrey J ^a,b   Martin Doyle, William ^c   Fay, André P ^a   Choueiri, Toni K ^a   Chang, Steven L ^a,b   Bellmunt, Joaquim ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; Chemotherapy; Kidney neoplasms; Neoadjuvant; Nephroureterectomy; Renal pelvic tumors; Upper tract urothelial carcinoma; Ureteral neoplasms; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CARCINOMA; DISEASE FREE SURVIVAL; HUMAN; KIDNEY NEOPLASMS; META ANALYSIS; SURVIVAL RATE; URETERAL NEOPLASMS; UROTHELIUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; PACLITAXEL; SURVIVAL RATE; URETERAL NEOPLASMS; UROTHELIUM;

EID: 84905906694     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.03.003     Document Type: Review

References (54)

1. M. Roupret, M. Babjuk, E. Comperat European Association of Urology European guidelines on upper tract urothelial carcinomas: 2013 update Eur Urol 63 2013 1059 1071
2. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202 206 discussion 205-6
3. J.J. Leow, W. Martin-Doyle, and P.S. Rajagopal et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials Eur Urol 66 2014 42 54
4. D.A. Green, M. Rink, and E. Xylinas et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins J Urol 189 2013 1214 1221
5. P.M. Cuckow, P. Nyirady, and P.J. Winyard Normal and abnormal development of the urogenital tract Prenat Diagn 21 2001 908 916
6. I. Riedel, F.X. Liang, and F.M. Deng et al. Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder? Eur J Cell Biol 84 2005 393 405
7. A.E. Hudson, W.C. Feng, C.F. Delostrinos, N. Carmean, and J.A. Bassuk Spreading of embryologically distinct urothelial cells is inhibited by SPARC J Cell Physiol 202 2005 453 463
8. J.W. Catto, A.R. Azzouzi, and N. Amira et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract Oncogene 22 2003 8699 8706
9. A. Hartmann, L. Zanardo, and T. Bocker-Edmonston et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract Cancer Res 62 2002 6796 6802
10. J.W. Catto, A.R. Azzouzi, and I. Rehman et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma J Clin Oncol 23 2005 2903 2910
11. E. Kunze, M. Wendt, and T. Schlott Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas Int J Mol Med 18 2006 547 557
12. M. Babjuk, M. Burger, and R. Zigeuner et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013 Eur Urol 64 2013 639 653
13. J. Bellmunt, and D.P. Petrylak New therapeutic challenges in advanced bladder cancer Semin Oncol 39 2012 598 607
14. J.M.M. van Oers, E.C. Zwarthoff, and I. Rehman et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours Eur Urol 55 2009 650 658
15. J.P. Sfakianos, P.H. Kim, and G. Iyer et al. Targeted sequencing of upper tract urothelial carcinoma [abstract] J Clin Oncol 32 2014 309
16. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 W64
17. D.F. Stroup, J.A. Berlin, and S.C. Morton et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2000 2008 2012
18. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
19. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
20. R. DerSimonian, and R. Kacker Random-effects model for meta-analysis of clinical trials: an update Contemp Clin Trials 28 2007 105 114
21. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
22. C.S. Berkey, D.C. Hoaglin, F. Mosteller, and G.A. Colditz A random-effects regression model for meta-analysis Stat Med 14 1995 395 411
23. M. Egger, G.D. Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
24. A. Bamias, C. Deliveliotis, and G. Fountzilas et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group J Clin Oncol 22 2004 2150 2154
25. S. Suzuki, N. Shinohara, T. Harabayashi, S. Sato, T. Abe, and T. Koyanagi Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer Int J Urol 11 2004 456 460
26. C. Kwak, S.E. Lee, I.G. Jeong, and J.H. Ku Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract Urology 68 2006 53 57
27. S.E. Lee, S.S. Byun, Y.H. Park, I.H. Chang, Y.J. Kim, and S.K. Hong Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract Urol Int 77 2006 22 26
28. N. Soga, K. Arima, and Y. Sugimura Adjuvant methotrexate, vinblastine, Adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma Int J Urol 15 2008 800 803
29. N.J. Hellenthal, S.F. Shariat, and V. Margulis et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration J Urol 182 2009 900 906
30. M. Vassilakopoulou, T. de la Motte Rouge, P. Colin French Collaborative National Database on UUT-UCC Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study Cancer 117 2011 5500 5508
31. A. Kawashima, Y. Nakai, and M. Nakayama et al. The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study World J Urol 30 2012 701 706
32. T.S. Kim, J.H. Oh, and H.Y. Rhew The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma J Cancer 4 2013 686 690
33. Yafi FA, Tanguay S, Rendon R, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol 2014;32:31.e17-24.
34. R.F. Youssef, S.F. Shariat, and Y. Lotan et al. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration BJU Int 108 2011 1286 1291
35. S.F. Matin, V. Margulis, and A. Kamat et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma Cancer 116 2010 3127 3134
36. V. Margulis, S.F. Shariat, S.F. Matin Upper Tract Urothelial Carcinoma Collaboration The Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration Cancer 115 2009 1224 1233
37. M. Igawa, S. Urakami, and H. Shiina et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract Urol Int 55 1995 74 77
38. A.O. Siefker-Radtke, C.P. Dinney, and Y. Shen et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results Cancer 119 2013 540 547
39. A. Siefker-Radtke, A. Kamat, and P. Corn et al. Neoadjuvant chemotherapy with DDMVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the M.D. Anderson Cancer Center [abstract] J Clin Oncol 30 2012 261
40. S.P. Porten, A.O. Siefker-Radtke, and A.M. Kamat et al. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma [abstract] J Clin Oncol 31 Suppl 6 2013 311
41. M.G. Kaag, R.L. O'Malley, and P. O'Malley et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy Eur Urol 58 2010 581 587
42. B.R. Lane, A.K. Smith, and B.T. Larson et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy Cancer 116 2010 2967 2973
43. Kaag M, Trost L, Thompson RH, et al. Pre-operative predictors of renal function decline following radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int. In press. http://dx.doi.org/10.1111/bju.12597.
44. A. Dechartres, I. Boutron, L. Trinquart, P. Charles, and P. Ravaud Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study Ann Intern Med 155 2011 39 51
45. M.D. Galsky, N.M. Hahn, and J. Rosenberg et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy J Clin Oncol 29 2011 2432 2438
46. B.A. Gayed, G.R. Thoreson, and V. Margulis The role of systemic chemotherapy in management of upper tract urothelial cancer Curr Urol Rep 14 2013 94 101
47. Johnson DC, Nielsen ME, Matthews J, et al. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU Int. In press. http://dx.doi.org/10.1111/bju.12585.
48. G. Gandaglia, I. Popa, and F. Abdollah et al. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study Eur Urol 66 2014 561 568
49. S. Porten, A. Siefker-Radtke, A. Kamat, C. Dinney, and S. Matin Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma [abstract] J Clin Oncol Suppl 6 2013 311
50. Reardon ZD, Patel SG, Zaid HB, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. In press. http://dx.doi.org/10.1016/j. eururo.2014.01.009.
51. A.J. Birtle, R. Lewis, M. Johnson, and E. Hall POUT Trial Management Group (TMG). Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) - opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) trial BJU Int 110 2012 919 921
52. M.M. Bertagnolli, D. Niedzwiecki, and C.C. Compton et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803 J Clin Oncol 27 2009 1814 1821
53. P.E. Clark, N. Agarwal, M.C. Biagioli National Comprehensive Cancer Network (NCCN) Bladder cancer J Natl Compr Canc Netw 11 2013 446 475
54. J.H. Hoffman-Censits, E.J. Trabulsi, and D.Y.T. Chen et al. Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma [abstract] J Clin Oncol 32 Suppl 4 2014 326